On March 09, 2022, the Moscow Arbitration Court satisfied the claim of Zentiva Pharma against Farmatun-1, Dinamika and MC Dinamika for the protection of patent rights in relation to Dolphin nasal washing device (utility model No.151,829). The Defendants were forbidden to sell, offer for sale and store for these purposes their medical product «Duolor».
Until 2018, Defendants were engaged in the production of devices and nasal washing products under the brand name «Dolphin» for Zentiva Pharma. After the transfer of production, they released under their brand a product «Duolor» similar to “Dolphin».
Defendants insisted that their device is manufactured according the utility model No 196,933 and does not contain «a dispenser having an axial channel» described in Zentiva’s patent. But this argument was refuted by the patent examination. Further, the Сourt noted that the Defendants’ reference to the later utility model No. 196933 does not influence on the consideration of this dispute regarding infringement of the Zentiva’s patent.
Thus, the Court found that the Defendants’ product «Duolor» contains every feature of the plaintiff’s utility model, and a permission of the patent owner for production and sale has not been obtained. The Court satisfied the claim and recovered from the defendants the costs of the examination.
Many trademarks may include non-protectable elements, which describe the type of goods these marks are…
Mongolia stands out as a rapidly developing market, representing significant opportunities for both East Asian…
Sega Corporation, a well-known Japanese video game producer has entered in an agreement with a…
The Eurasian Patent Organization will be raising the fees for several services starting from February…
In 1995, the Eurasian Patent Convention (EAPC) was established to create a unified patent space,…